Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | Chief Legal Officer | September 16, 2026 | September 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date September 16, 2026 · Filed September 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,617 |
Ending reported balance
After 2026-09-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-16 · Exercise / conversion · Acquired 1,635 · Balance 10,252 Row 2 · 2026-09-16 · Sale · Disposed 1,635 · Balance 8,617 F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2035-03-05 | Direct | 58,066 |
Reported balance
After 2026-09-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-16 · Exercise / conversion · Disposed 1,635 · Balance 58,066 F2: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.
F2: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 22, 2026 22:43 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,635 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001193125-26-398204 · ownership.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,066 Underlying: Common Stock · 1,635 shares Expires 2035-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| September 16, 2026 Filed Sep 22, 2026 22:43 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,635 | $13.65 | $22,317.75 |
DisclosureSEC source: 0001193125-26-398204 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,617 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. Read SEC document |
| September 16, 2026 Filed Sep 22, 2026 22:43 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,635 | $4.14 | $6,768.90 |
DisclosureSEC source: 0001193125-26-398204 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 22:55 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 584 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001193125-26-382245 · ownership.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,959 Underlying: Common Stock · 584 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 22:55 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 584 | $14.00 | $8,176.00 |
DisclosureSEC source: 0001193125-26-382245 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,617 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 22:55 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 584 | $6.49 | $3,790.16 |
DisclosureSEC source: 0001193125-26-382245 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. Read SEC document |
| August 17, 2026 Filed Aug 17, 2026 21:34 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,635 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001193125-26-354313 · ownership.xml · derivative · entry 6 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,701 Underlying: Common Stock · 1,635 shares Expires 2035-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| August 17, 2026 Filed Aug 17, 2026 21:34 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,635 | $12.20 | $19,947.00 |
DisclosureSEC source: 0001193125-26-354313 · ownership.xml · nonDerivative · entry 4 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,617 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. Read SEC document |
| August 17, 2026 Filed Aug 17, 2026 21:34 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,635 | $4.14 | $6,768.90 |
DisclosureSEC source: 0001193125-26-354313 · ownership.xml · nonDerivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 21:34 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,635 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001193125-26-354313 · ownership.xml · derivative · entry 5 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,336 Underlying: Common Stock · 1,635 shares Expires 2035-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 21:34 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,635 | $12.00 | $19,620.00 |
DisclosureSEC source: 0001193125-26-354313 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,617 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. Read SEC document |
| August 13, 2026 Filed Aug 17, 2026 21:34 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,635 | $4.14 | $6,768.90 |
DisclosureSEC source: 0001193125-26-354313 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:07 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,752 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001920738-26-000004 · ownership.xml · derivative · entry 5 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,543 Underlying: Common Stock · 5,752 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:07 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 814 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001920738-26-000004 · ownership.xml · derivative · entry 4 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,971 Underlying: Common Stock · 814 shares Expires 2035-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:07 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 6,566 | $14.00 | $91,924.00 |
DisclosureSEC source: 0001920738-26-000004 · ownership.xml · nonDerivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,617 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:07 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 5,752 | $6.49 | $37,330.48 |
DisclosureSEC source: 0001920738-26-000004 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:07 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 814 | $4.14 | $3,369.96 |
DisclosureSEC source: 0001920738-26-000004 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:38 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,810 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001920738-26-000002 · ownership.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,785 Underlying: Common Stock · 9,810 shares Expires 2035-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:38 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 9,810 | $12.00 | $117,720.00 |
DisclosureSEC source: 0001920738-26-000002 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,617 Read SEC document |
| June 23, 2026 Filed Jun 25, 2026 20:38 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 9,810 | $4.14 | $40,613.40 |
DisclosureSEC source: 0001920738-26-000002 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects 5,023 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| March 25, 2026 Filed Mar 27, 2026 20:30 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 217,000 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001193125-26-129155 · ownership.xml · derivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,000 Underlying: Common Stock · 217,000 shares Expires 2036-03-24 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 21:10 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,635 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001193125-25-326851 · ownership.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,595 Underlying: Common Stock · 1,635 shares Expires 2035-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 21:10 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,635 | $10.90 | $17,821.50 |
DisclosureSEC source: 0001193125-25-326851 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,594 Read SEC document |
| December 16, 2025 Filed Dec 19, 2025 21:10 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,635 | $4.14 | $6,768.90 |
DisclosureSEC source: 0001193125-25-326851 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 02:53 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,635 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001193125-25-288632 · ownership.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,230 Underlying: Common Stock · 1,635 shares Expires 2035-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 02:53 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,635 | $10.59 | $17,314.65 |
DisclosureSEC source: 0001193125-25-288632 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,594 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. Read SEC document |
| November 17, 2025 Filed Nov 20, 2025 02:53 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,635 | $4.14 | $6,768.90 |
DisclosureSEC source: 0001193125-25-288632 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,229 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. Read SEC document |
| October 24, 2025 Filed Oct 27, 2025 22:19 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,084 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0001193125-25-251874 · ownership.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,295 Underlying: Common Stock · 1,084 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| October 24, 2025 Filed Oct 27, 2025 22:19 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 2,678 | $12.00 | $32,136.00 |
DisclosureSEC source: 0001193125-25-251874 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,594 Read SEC document |
| October 24, 2025 Filed Oct 27, 2025 22:19 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,084 | $6.49 | $7,035.16 |
DisclosureSEC source: 0001193125-25-251874 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2025 Filed Oct 20, 2025 23:51 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,635 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0001193125-25-243946 · ownership.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,865 Underlying: Common Stock · 1,635 shares Expires 2035-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| October 16, 2025 Filed Oct 20, 2025 23:51 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,635 | $10.17 | $16,627.95 |
DisclosureSEC source: 0001193125-25-243946 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,188 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. Read SEC document |
| October 16, 2025 Filed Oct 20, 2025 23:51 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,635 | $4.14 | $6,768.90 |
DisclosureSEC source: 0001193125-25-243946 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. Read SEC document |
| October 09, 2025 Filed Oct 14, 2025 20:04 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 2,408 | $10.00 | $24,080.00 |
DisclosureSEC source: 0001193125-25-238995 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,188 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. Read SEC document |
| September 23, 2025 Filed Sep 27, 2025 01:50 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 2,407 | $8.00 | $19,256.00 |
DisclosureSEC source: 0001193125-25-221028 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,596 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025. F2 · balance_after: Reflects 3,222 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| March 06, 2025 Filed Mar 11, 2025 00:00 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 78,500 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0000950170-25-036696 · ownership.xml · derivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,500 Underlying: Common Stock · 78,500 shares Expires 2035-03-05 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:46 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 500 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0000950170-24-107903 · ownership.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,379 Underlying: Common Stock · 500 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:46 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 500 | $16.33 | $8,165.00 |
DisclosureSEC source: 0000950170-24-107903 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,781 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:46 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 500 | $6.49 | $3,245.00 |
DisclosureSEC source: 0000950170-24-107903 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:28 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 500 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0000950170-24-099505 · ownership.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,879 Underlying: Common Stock · 500 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:28 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 500 | $15.00 | $7,500.00 |
DisclosureSEC source: 0000950170-24-099505 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,781 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:28 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 500 | $6.49 | $3,245.00 |
DisclosureSEC source: 0000950170-24-099505 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| July 16, 2024 Filed Jul 19, 2024 00:22 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,250 | $0.00 Strike: $8.04 | $0.00 |
DisclosureSEC source: 0000950170-24-084725 · ownership.xml · derivative · entry 5 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,502 Underlying: Common Stock · 1,250 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| July 16, 2024 Filed Jul 19, 2024 00:22 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 500 | $0.00 Strike: $6.49 | $0.00 |
DisclosureSEC source: 0000950170-24-084725 · ownership.xml · derivative · entry 4 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,379 Underlying: Common Stock · 500 shares Expires 2032-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F2 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| July 16, 2024 Filed Jul 19, 2024 00:22 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,750 | $27.11 | $47,442.50 |
DisclosureSEC source: 0000950170-24-084725 · ownership.xml · nonDerivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,781 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| July 16, 2024 Filed Jul 19, 2024 00:22 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,250 | $8.04 | $10,050.00 |
DisclosureSEC source: 0000950170-24-084725 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| July 16, 2024 Filed Jul 19, 2024 00:22 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 500 | $6.49 | $3,245.00 |
DisclosureSEC source: 0000950170-24-084725 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| July 11, 2024 Filed Jul 15, 2024 22:13 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionStock Option (Right To Buy) · Derivative | 1,996 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0000950170-24-083712 · ownership.xml · derivative · entry 3 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,004 Underlying: Common Stock · 1,996 shares Expires 2032-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F3 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 1, 2022 (the "Vesting Commencement Date") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| July 11, 2024 Filed Jul 15, 2024 22:13 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | SaleCommon Stock | 1,996 | $25.00 | $49,900.00 |
DisclosureSEC source: 0000950170-24-083712 · ownership.xml · nonDerivative · entry 2 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,781 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. Read SEC document |
| July 11, 2024 Filed Jul 15, 2024 22:13 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | Exercise / conversionCommon Stock | 1,996 | $15.78 | $31,496.88 |
DisclosureSEC source: 0000950170-24-083712 · ownership.xml · nonDerivative · entry 1 Bizily Scott · CIK 0001920738 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023. F2 · balance_after: Reflects 5,044 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.